The association of oncogenic KMT2A-fusion proteins with Menin and LEDGF is required for its chromatin binding, target gene expression such as the HOXA9 and MEIS1, and implicated the Menin-KMT2A interaction as a therapeutic opportunity in these leukemias [36, 37]. The gene discussed is KMT2A; the disease is leukemia.